Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide (SEMA SMA)
Alleviating Carbohydrate Counting Using Weekly Subcutaneous Semaglutide Injections in People With Type 1 Diabetes on Closed-Loop Insulin Therapy: a 2x4 Factorial Randomized Placebo-Controlled Trial
A closed-loop insulin system, often labelled the "artificial pancreas" (AP), consists of an insulin pump, a continuous glucose monitor, and an interface coordinating between them to regulate insulin dosage based on glucose levels. Primarily designed for managing type 1 diabetes, this system has demonstrated significant benefits in previous studies. Yet, despite these advantages, certain challenges persist.
Semaglutide, utilized in treating type 2 diabetes and obesity, is a once-weekly injectable medication that elevates levels of a gastrointestinal hormone known as Glucagon-Like Peptide-1 (GLP-1). This hormone alters gastric emptying, inhibits glucagon release, and reduces appetite. While not officially sanctioned for type 1 diabetes treatment in North America, studies have explored its efficacy as an adjunctive therapy alongside insulin, yielding favorable outcomes in blood glucose regulation. Comparable drugs like liraglutide and exenatide have been employed in type 1 diabetes treatment as well, albeit with less pronounced glucose-regulating effects compared to semaglutide, even in type 2 diabetes.
The goal of this 50-week randomized placebo-controlled crossover 2x4 factorial designed trial is to assess whether commercial automated insulin delivery (AID) systems using rapid-acting insulin with adjunct weekly injections of semaglutide (at the maximally tolerated dose) can replace carbohydrate counting with simple meal announcements (SMA) without degrading glucose control.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The main questions this study aims to answer are:
-
Can weekly injections of semaglutide at the maximum tolerated dose in individuals with T1D on closed-loop therapy with SMA and rapid-acting insulin result in a non-inferior time spent in target range (3.9-10 mmol/L) compared to weekly placebo injections on closed-loop system with full carbohydrate counting.
-
Can weekly injections of semaglutide at the maximum tolerated dose, in combination with ultra-rapid actin insulin (Lyumjev);
- Eliminate carbohydrate counting and any meal announcement (i.e fully closed-loop) in people with T1D on closed-loop therapy without degrading glucose control.
- Be more effective in substituting carbohydrate counting with SMA in people with T1D on closed-loop therapy compared with traditional rapid-acting insulin.
Participants will be asked to undergo two subsequent blinded drug interventions; one with semaglutide and the other with placebo. Both interventions include 4 meal strategies each with a 3-week duration; full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Carolyn Wright, B.Sc.
- 電話番号:(514) 318-7298
- メール:carolyn.wright@mail.mcgill.ca
研究連絡先のバックアップ
- 名前:Keddy Moise, B.Sc.
- 電話番号:(438) 531-6896
- メール:keddy.moise@affiliate.mcgill.ca
研究場所
-
-
Quebec
-
Montreal、Quebec、カナダ、H4A 3J1
- 募集
- Research Institute of the McGill University Health Centre
-
主任研究者:
- Michael Tsoukas, MD
-
副調査官:
- Ahmad Haidar, Ph.D
-
副調査官:
- Vanessa Tardio, MD
-
コンタクト:
- Carolyn Wright, B.Sc.
- 電話番号:(514) 318-7298
- メール:carolyn.wright@mail.mcgill.ca
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- At least 18 years of age
- A clinical diagnosis of T1D for at least one year, as per their treating diabetes physician in agreement with the primary investigator's clinical judgment (confirmatory C-peptide and antibodies will not be required)
- Minimum 3-month use of a commercial advanced automated insulin delivery system. 4.4. Agreement to use an effective method of birth control for individuals with child-bearing potential. Child-bearing potential refers to participants of the female sex post-menarche who have not reached menopause and who do not have a medical condition causing sterility (e.g., hysterectomy). Post-menopausal state refers to the absence of menses for 12 months without any alternative cause.
Exclusion Criteria:
- Use of GLP1-RAs within the last 4 weeks.
- Use of any anti-hyperglycemic agent other than insulin within the last 2 weeks.
- Planned or ongoing pregnancy
- Breastfeeding
- Severe hypoglycemic episode within the last 3 months, defined as an event where glucose was < 4 mmol/L resulting in seizure, loss of consciousness, or need to present to the emergency department
- Severe diabetic ketoacidosis (DKA) within the last 6 months ("severe" referring to need to present to medical attention and requirement of intravenous insulin)
- Prior history of acute pancreatitis, chronic pancreatitis, or gallbladder disease
- Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
- Severe impairment of renal function with eGFR <30 mL/min/1.73 m2 (using CKD-EPI formula), measured within the last 12 months
- Clinically significant diabetic retinopathy or gastroparesis, as per the clinical judgment of the investigator
- Bariatric surgery within the last 6 months.
- A serious medical or psychiatric illness that is likely to interfere with study participation as per the judgment of the investigator (e.g. cirrhosis, active cancer, decompensated schizophrenia).
- Body mass index ≤ 21 kg/m2
- Inability or unwillingness to comply to safe diabetes management in the view of the study group (e.g. inappropriate treatment of hypoglycemia or lack thereof)
- Concern for safety of the participant, as per the clinical judgment of the primary investigator
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:定期的な閉ループインスリンポンプ療法における毎週のプラセボ注射
|
The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order. |
|
実験的:Weekly semaglutide (Ozempic®) injections on regular closed-loop insulin pump therapy
Semaglutide is a Glucagon-like peptide 1 (GLP-1) receptor agonist. It up regulates GLP-1, which reduces glucagon levels, increases satiety and - in some particular cases - increases insulin production. It will be subcutaneously injected weekly by participants at progressively increasing doses. Once the maximum tolerated dose is achieved, participants will begin the meal strategies. |
The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo)
時間枠:24 weeks
|
Target range is defined to be between 3.9 and 10.0 mmol/L of plasma glucose for placebo vs semaglutide (at maximal tolerated dose) on closed-loop insulin therapy |
24 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of time spent in the range of glucose levels between 3.9 and 7.8 mmol/L
時間枠:24 weeks
|
% as per CGM data |
24 weeks
|
|
Percentage of time spent in glucose levels below 3.9 and 3.0 mmol/L
時間枠:24 weeks
|
% as per CGM data |
24 weeks
|
|
Percentage of time spent in glucose levels above 7.8, 10 and 13.9 mmol/L
時間枠:24 weeks
|
% as per CGM data |
24 weeks
|
|
Mean glucose level
時間枠:24 weeks
|
Defined as per CGM data, in mmol/L |
24 weeks
|
|
Standard deviation of glucose levels as a measure of glucose variability
時間枠:24 weeks
|
Defined as per CGM data, in mmol/L |
24 weeks
|
|
Percentage coefficient of variation of glucose levels
時間枠:24 weeks
|
% as per CGM data |
24 weeks
|
|
Proportions of participants with time in range between 3.9 - 10.0 mmol/L≥ 70%
時間枠:24 weeks
|
As per CGM data |
24 weeks
|
|
Glycated hemoglobin (HbA1c)
時間枠:24 weeks
|
Blood test to assess glucose control within 3-4 months |
24 weeks
|
|
Area under the curve 0-2h post meal, 0-3h post peal
時間枠:24 weeks
|
As per CGM data |
24 weeks
|
|
Average scores between interventions on the Type 1 Diabetes Distress Scale questionnaire
時間枠:24 weeks
|
17-item questionnaire with a 6-point Likert scale from 1 (no stress) to 6 (high stress) for each item. Total score obtained from summing the scores of all items |
24 weeks
|
|
Average scores between interventions on the Diabetes Treatment Satisfaction questionnaire
時間枠:24 weeks
|
8-item questionnaire with a 7-point Likert scale ranging from 0 (low satisfaction) to 6 (high satisfaction). Total score obtained from summing the scores of all items. |
24 weeks
|
|
Average scores between interventions based on the Hypoglycemic Fear Survey - II
時間枠:24 weeks
|
33-item questionnaire with a 5-point Likert scale ranging from 1 (never) to 5 (almost always). Total score obtained from summing the scores of all items. |
24 weeks
|
|
Heart rate
時間枠:24 weeks
|
Beats per minute |
24 weeks
|
|
Blood pressure
時間枠:24 weeks
|
mmHg |
24 weeks
|
|
Measure of body weight
時間枠:24 weeks
|
Measurements done at visit - weight in kilograms |
24 weeks
|
|
Measure of body mass index
時間枠:24 weeks
|
Measurements done at visit - body mass index as per kg/m^2 |
24 weeks
|
|
Measure of waist circumference and hip circumference
時間枠:24 weeks
|
Measurements done at visit - circumference in cm |
24 weeks
|
|
Measure of waist-to-hip ratio
時間枠:24 weeks
|
Measurements done at visit |
24 weeks
|
|
Lipid profile, specifically: LDL-cholesterol, HDL-cholesterol, triglycerides
時間枠:24 weeks
|
Blood tests, in mmol/L |
24 weeks
|
|
Urine albumin-creatinine ratio
時間枠:24 weeks
|
Urine test |
24 weeks
|
協力者と研究者
スポンサー
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 2024-10227
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The raw data (that is, insulin delivery, glucose levels and individual participant data) and informed consent form will be shared by the corresponding author, for academic purposes, subject to a material transfer agreement and approval of the McGill University Health Center's Research Ethics Board. All data shared will be de-identified. Raw data will be shared for non-commercial use upon reasonable request and a material transfer agreement.
IPD 共有サポート情報タイプ
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。